|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 6 (March 15), 1999:
pp. 1790-1797
Sustained Induction of Fetal Hemoglobin by Pulse Butyrate Therapy in
Sickle Cell Disease
George F. Atweh,
Millicent Sutton,
Imad Nassif,
Vassiliki Boosalis,
George J. Dover,
Sylvan Wallenstein,
Elizabeth Wright,
Lillian McMahon,
George Stamatoyannopoulos,
Douglas V. Faller, and
Susan P. Perrine
From the Departments of Medicine, Pediatrics and Biomathematical
Sciences, Mount Sinai School of Medicine, New York, NY; the Departments
of Pediatrics, Medicine, Pharmacology, and Experimental Therapeutics,
Hemoglobinopathy-Thalassemia Research Unit, Boston University School of
Medicine, Boston, MA; the Department of Pediatrics, Johns Hopkins
University School of Medicine, Baltimore, MD; the Division of Medical
Genetics, University of Washington School of Medicine, Seattle, WA; and
The New England Research Institute, Watertown, MA.
High levels of fetal hemoglobin (Hb F) protect from many of the
complications of sickle cell disease and lead to improved survival.
Butyrate and other short chain fatty acids were previously shown to
increase Hb F production in erythroid cells in vitro and in animal
models in vivo. However, butyrates are also known to inhibit the
proliferation of many cell types, including erythroid cells. Experience
with the use of butyrate in animal models and in early clinical trials
demonstrated that the Hb F response may be lost after prolonged
administration of high doses of butyrate. We hypothesized that this
loss of response may be a result of the antiproliferative effects of
butyrate. We designed a regimen consisting of intermittent or pulse
therapy in which butyrate was administered for 4 days followed by 10 to
24 days with no drug exposure. This pulse regimen induced fetal globin
gene expression in 9 of 11 patients. The mean Hb F in this group
increased from 7.2% to 21.0% (P < .002) after intermittent
butyrate therapy for a mean duration of 29.9 weeks. This was associated
with a parallel increase in the number of F cells and F reticulocytes.
The total hemoglobin levels also increased from a mean of 7.8 g/dL to a mean of 8.8 g/dL (P < .006). The increased levels of Hb F
were sustained in all responders, including 1 patient who has been on
pulse butyrate therapy for more than 28 months. This regimen, which
resulted in a marked and sustained increase in Hb F levels in more than
two thirds of the adult sickle cell patients enrolled in this study,
was well tolerated without adverse side effects. These encouraging
results require confirmation along with an appropriate evaluation of
clinical outcomes in a larger number of patients with sickle cell disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Mai, K. Jelicic, D. Rotili, A. Di Noia, E. Alfani, S. Valente, L. Altucci, A. Nebbioso, S. Massa, R. Galanello, et al.
Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia
Mol. Pharmacol.,
November 1, 2007;
72(5):
1111 - 1123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Fathallah, R. S. Weinberg, Y. Galperin, M. Sutton, and G. F. Atweh
Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin
Blood,
November 1, 2007;
110(9):
3391 - 3397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Perrine, O. Hermine, T. Small, F. Suarez, R. O'Reilly, F. Boulad, J. Fingeroth, M. Askin, A. Levy, S. J. Mentzer, et al.
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
Blood,
March 15, 2007;
109(6):
2571 - 2578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mercuri, E. Bertini, S. Messina, A. Solari, A. D'Amico, C. Angelozzi, R. Battini, A. Berardinelli, P. Boffi, C. Bruno, et al.
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy
Neurology,
January 2, 2007;
68(1):
51 - 55.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mankidy, D. V. Faller, R. Mabaera, C. H. Lowrey, M. S. Boosalis, G. L. White, S. A. Castaneda, and S. P. Perrine
Short-chain fatty acids induce {gamma}-globin gene expression by displacement of a HDAC3-NCoR repressor complex
Blood,
November 1, 2006;
108(9):
3179 - 3186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Perrine
Hemoglobin F: new targets, new path
Blood,
August 1, 2006;
108(3):
783 - 784.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bank
Regulation of human fetal hemoglobin: new players, new complexities
Blood,
January 15, 2006;
107(2):
435 - 443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Fathallah and G. F. Atweh
Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease
Hematology,
January 1, 2006;
2006(1):
58 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Weinberg, X. Ji, M. Sutton, S. Perrine, Y. Galperin, Q. Li, S. A. Liebhaber, G. Stamatoyannopoulos, and G. F. Atweh
Butyrate increases the efficiency of translation of {gamma}-globin mRNA
Blood,
February 15, 2005;
105(4):
1807 - 1809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hanawa, P. W. Hargrove, S. Kepes, D. K. Srivastava, A. W. Nienhuis, and D. A. Persons
Extended {beta}-globin locus control region elements promote consistent therapeutic expression of a {gamma}-globin lentiviral vector in murine {beta}-thalassemia
Blood,
October 15, 2004;
104(8):
2281 - 2290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Cao, G. Stamatoyannopoulos, and M. Jung
Induction of human {gamma} globin gene expression by histone deacetylase inhibitors
Blood,
January 15, 2004;
103(2):
701 - 709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Wright, P. L. Zeitlin, L. Cebotaru, S. E. Guggino, and W. B. Guggino
Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins
Physiol Genomics,
January 15, 2004;
16(2):
204 - 211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Buchanan, M. R. DeBaun, C. T. Quinn, and M. H. Steinberg
Sickle Cell Disease
Hematology,
January 1, 2004;
2004(1):
35 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Atweh
Hypomethylation therapy for hemoglobin disorders is back at center stage
Blood,
December 1, 2003;
102(12):
3855 - 3856.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Dempsey, L. S. Ojalvo, D. W. Wu, and J. A. Little
Induction of an embryonic globin gene promoter by short-chain fatty acids
Blood,
December 1, 2003;
102(12):
4214 - 4222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gabbianelli, U. Testa, A. Massa, O. Morsilli, E. Saulle, N. M. Sposi, E. Petrucci, G. Mariani, and C. Peschle
HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone
Blood,
April 1, 2003;
101(7):
2826 - 2832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Wojda, K. R. Leigh, J. M. Njoroge, K. A. Jackson, B. Natarajan, M. Stitely, and J. L. Miller
Fetal hemoglobin modulation during human erythropoiesis: stem cell factor has "late" effects related to the expression pattern of CD117
Blood,
January 15, 2003;
101(2):
492 - 497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho
Myelodysplastic Syndrome
Hematology,
January 1, 2003;
2003(1):
176 - 199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Pace, G. L. White, G. J. Dover, M. S. Boosalis, D. V. Faller, and S. P. Perrine
Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo
Blood,
December 15, 2002;
100(13):
4640 - 4648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Emery, E. Yannaki, J. Tubb, T. Nishino, Q. Li, and G. Stamatoyannopoulos
Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma -globin gene silencing in vivo
Blood,
August 28, 2002;
100(6):
2012 - 2019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Boosalis, R. Bandyopadhyay, E. H. Bresnick, B. S. Pace, K. Van DeMark, B. Zhang, D. V. Faller, and S. P. Perrine
Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation
Blood,
May 15, 2001;
97(10):
3259 - 3267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ikuta, S. Ausenda, and M. D. Cappellini
Mechanism for fetal globin gene expression: Role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway
PNAS,
February 1, 2001;
(2001)
41599798.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. D. Smith, J. D. Malley, and A. N. Schechter
Quantitative analysis of globin gene induction in single human erythroleukemic cells
Nucleic Acids Res.,
December 15, 2000;
28(24):
4998 - 5004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Maeda, M. Towatari, H. Kosugi, and H. Saito
Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells
Blood,
December 1, 2000;
96(12):
3847 - 3856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Reich, C. Buhrer, G. Henze, D. Ohlendorf, M. Mesche, P. Sinha, A. Kage, C. Muller, B. Vetter, and A. E. Kulozik
Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta -thalassemia
Blood,
November 15, 2000;
96(10):
3357 - 3363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Koshy, L. Dorn, L. Bressler, R. Molokie, D. Lavelle, N. Talischy, R. Hoffman, W. van Overveld, and J. DeSimone
2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia
Blood,
October 1, 2000;
96(7):
2379 - 2384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gabbianelli, U. Testa, A. Massa, E. Pelosi, N. M. Sposi, R. Riccioni, L. Luchetti, and C. Peschle
Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate
Blood,
June 1, 2000;
95(11):
3555 - 3561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Witt, K. Sand, and A. Pekrun
Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways
Blood,
April 1, 2000;
95(7):
2391 - 2396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Smith, J. Li, C. T. Noguchi, and A. N. Schechter
Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells
Blood,
February 1, 2000;
95(3):
863 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. F. Rosse, M. Narla, L. D. Petz, and M. H. Steinberg
New Views of Sickle Cell Disease Pathophysiology and Treatment
Hematology,
January 1, 2000;
2000(1):
2 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. F. Olivieri
The {beta}-Thalassemias
N. Engl. J. Med.,
July 8, 1999;
341(2):
99 - 109.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. F. Bunn
Induction of Fetal Hemoglobin in Sickle Cell Disease
Blood,
March 15, 1999;
93(6):
1787 - 1789.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ikuta, S. Ausenda, and M. D. Cappellini
Mechanism for fetal globin gene expression: Role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway
PNAS,
February 13, 2001;
98(4):
1847 - 1852.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
